leisure time -WSS

leisure time

author：fashion 2025-10-01 02:27:39 - browse：3

Home health and hospice chain Amedisys has chosen a new corporate owner.

Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Wikipedia

WSS

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

What causes an itch? Researchers may have solved the mystery

Judge rejects Trump's request to move Stormy Daniels hush

Pfizer plans to depart BIO

Affordable Connectivity Program vital to health care, experts say

entertainment

leisure time

explore

Moonlake's readout produced a cash windfall. Risks remain

Supreme Court wrestles with OxyContin maker's bankruptcy deal

The cancer drug shortage isn’t new — and neither are the solutions

Chemotherapy shortages won’t get better under Biden’s latest plan

DIEP, the 'gold standard' of breast reconstruction, is under threat

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

United colonoscopy coverage change 'may cost lives,' doctors say

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Heart attack and stroke risk calculators need revising

I learned firsthand about improving diversity in clinical trials

focus

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Leukemia patients are helped by Syndax's new type of therapy

Judge rejects Trump's request to move Stormy Daniels hush

Chemotherapy shortages won’t get better under Biden’s latest plan

Pregnancy discrimination could be enabled by AI

Tesla recalling nearly 16,000 of its 2021

focus

focus

Wikipedia

knowledge